Body Handbook კატალოგი პროფილი რეიტინგი
ნაწლავები BODY HANDBOOK
ნაწლავები · §73
IBD: ბიოლოგიური წამალი პირველ რიგში
Just diagnosed with moderate or severe Crohn's or ulcerative colitis? Which drug you start on is your first real decision, and the standard path gets it backwards. It saves the biologic injection for last: steroids first, a stronger pill if those fail, biologic only after years of worsening disease. Lead with the biologic from week one instead, and a year later 79% of Crohn's patients are in lasting remission without steroids or surgery, versus 15% on the slow route. The "cautious" path does the damage.
გადაწყვიტე · ერთხელ მტკიცებულება ძლიერი თავი ნაწლავები

Crohn's and ulcerative colitis are the immune system attacking the gut lining, driven by a signal protein called TNF-α. Biologics shut that signal down; a steroid only muffles it. Moving early is mechanical: Crohn's has a short inflammatory window of months to a few years, then it scars the bowel, and no drug dissolves scar tissue. Calm the gut before scarring starts.

Four trials asked the same question and all four agreed: leading with the biologic beats building up slowly. In 2024, 79% of top-down patients hit steroid-free, surgery-free remission at a year versus 15% on step-up, with fewer serious adverse events (15 vs 42) and fewer surgeries (1 vs 10) 1. The 2008 trial that coined "top-down" found 60% versus 36% 2. Both gastroenterology societies now suggest an advanced therapy over steroids first in moderate-to-severe disease 3.

The step-up years cost more than they look. Of newly-diagnosed Crohn's patients put on a steroid course, 28% became steroid-dependent within a year and 38% needed surgery in that same year 4. And that is while the steroid does its own damage: puffy face, wrecked sleep, weight gain, mood swings, and the disease still scarring the bowel underneath. The drug meant to be a bridge becomes the road.

The pairing isn't optional: the immunomodulator cuts the rate at which your body neutralises the biologic from 13% to 4% 5.

The forecast, rung by rung.

  • First six weeks: the 3 a.m. bathroom run stops, the daily count drops from eight or ten to two or three, stool blood fades.
  • Three months: energy returns; you stop mapping every trip around bathrooms.
  • One year: the colonoscopy shows normal tissue in most top-down patients, which predicts far fewer flares and surgeries.
  • Five years: durable remission, no excess infections or cancers, most still on the drug they started with 1.
The fine print — when to skip it, and what people get wrong

"A blood test can tell us who needs the strong drug." The best T-cell biomarker added nothing; every subgroup did better top-down. "Step-up is safer." Against cumulative steroids plus ongoing inflammation, top-down shows no excess infections or cancers 6.

Swap anti-TNF for a different biologic class with active infection (especially untreated latent TB), severe heart failure, multiple sclerosis, or recent lymphoma. Pregnancy is not a reason to delay; anti-TNF continues through it because uncontrolled disease is the bigger risk 7.

One in four to one in three don't respond to a first anti-TNF drug 8. If nothing improves by week 12 to 14, check drug levels, then switch class rather than trying a second anti-TNF.

References
  1. 1Noor et al. (2024). A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trial. Lancet Gastroenterology & Hepatology. link
  2. 2D'Haens et al. (2008). Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet. link
  3. 3Singh et al. (2025). AGA Living Clinical Practice Guideline on the Pharmacologic Management of Moderate-to-Severe Crohn's Disease. Gastroenterology. link
  4. 4Faubion et al. (2001). The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology. link
  5. 5Colombel et al. (2010). Infliximab, azathioprine, or combination therapy for Crohn's disease. New England Journal of Medicine. link
  6. 6Singh et al. (2020). Comparative risk of serious infections with biologic and/or immunosuppressive therapy in patients with inflammatory bowel diseases: a systematic review and meta-analysis. Clinical Gastroenterology and Hepatology. link
  7. 7Gordon et al. (2024). ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment. Journal of Crohn's and Colitis. link
  8. 8Kennedy et al. (2019). Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study (PANTS). Lancet Gastroenterology & Hepatology. link
დაკავშირებული სახელმძღვანელოში (5)
დაკავშირებული
  • — Before starting an immune-suppressing biologic, check this schedule: some shots must be given first, and live vaccines after may be off-limits.
  • — For ulcerative colitis, curcumin as an add-on cut relapse fourfold — handy alongside, not instead of, the biologic doing the heavy lifting.
  • — HS and Crohn's travel together and respond to the same TNF biologics, so one diagnosis can change how the other is treated.
  • — Catching IBD early through its red flags is what makes the top-down biologic strategy possible.
  • — Same class of drug, different disease — biologics that shut inflammation down at the source.
·
73